Malignant Solid Tumor Clinical Trial
Official title:
A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin
This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2). If MTD is not reached in Part 1, RP2D will be determined after completion of Part 1 considering safety and tolerability, also beyond the dose limiting toxicity (DLT) period, pharmacokinetic (PK) and pharmacodynamic (PD) results.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01846429 -
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
|
Phase 1 | |
| Completed |
NCT01359982 -
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
|
Phase 1 | |
| Completed |
NCT01648764 -
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
|
Phase 1 | |
| Completed |
NCT00725634 -
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05141474 -
Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
|
Early Phase 1 | |
| Active, not recruiting |
NCT02999750 -
EXtendedAnalysis for Cancer Treatment
|
N/A | |
| Completed |
NCT01457118 -
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
|
Phase 2 | |
| Active, not recruiting |
NCT05539157 -
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04571892 -
A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05468359 -
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04168528 -
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04145622 -
Study of Ifinatamab Deruxtecan (I-DXd) in Participants With Advanced Solid Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06057038 -
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT02844400 -
Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation
|
||
| Completed |
NCT00452413 -
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03553108 -
A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
|
Phase 1 | |
| Recruiting |
NCT04076137 -
Targeted T-cell Therapy in Solid Tumors
|
Early Phase 1 | |
| Terminated |
NCT03192345 -
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02754141 -
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
|
Phase 1/Phase 2 |